LDLRAD3

Across TCGA pan-cancer cohorts, LDLRAD3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LDLRAD3 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LDLRAD3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated LDLRAD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LAML, and CESC are the cancer types where LDLRAD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.925	0.437	.025	16	view →
LAML	DFS	Median	All	0.140	0.582	.020	12	view →
CESC	DFS	Median	All	0.070	0.823	<.001	12	view →
LIHC	DFS	Median	All	0.029	0.556	<.001	12	view →
COAD	DFS	Median	All	0.137	0.563	.016	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LDLRAD3–UCEC (DFS)

Open the UCEC breakdown →